Mayne Pharma | MYX - Cash And Equivalent

Stock Price
4.50
Daily Change
-0.78 -14.77%
Monthly
-10.00%
Yearly
-6.44%
Q3 Forecast
5.25

Mayne Pharma reported AUD110.07M in Cash and Equivalent for its fiscal semester ending in June of 2024.



Financials
Stock Price AUD
Assets AUD 1.14B
Cash and Equivalent AUD 110.07M
Cost of Sales AUD 43.74M
Current Assets AUD 460.59M
Current Liabilities AUD 313.94M
Debt AUD 38.82M
Dividend Yield 0
EBIT AUD -16.2M
EBITDA AUD -65.76M
Employees 900
EPS Earnings Per Share AUD -0.89
Equity Capital and Reserves AUD 454.19M
Gross Profit on Sales AUD 115.99M
Interest Expense on Debt AUD 1.2M
Loan Capital AUD 31.64M
Market Capitalization AUD 382.83M
Net Income AUD -103.68M
Operating Expenses AUD 103.54M
Operating Profit AUD -3.3M
Ordinary Share Capital AUD 1.22B
Pre-Tax Profit AUD -57.61M
Sales Revenues AUD 195.04M
Selling and Administration Expenses AUD 54.8M
Stock AUD 74.63M
Trade Creditors AUD 20.87M
Trade Debtors AUD 193.22M

Cash And Equivalent Change Date
Ansell USD 912.3M 747.2M Jun/2024
Avita Medical AUD 14.05M 3.4M Dec/2024
Cochlear AUD 383.1M 130.5M Dec/2024
CSL USD 1.52B 133M Dec/2024
Healius AUD 60.1M 25.6M Jun/2024
Integral Diagnostics AUD 17.99M 15.86M Dec/2023
Medical Developments International AUD 17.62M 7.88M Dec/2024
Nanosonics AUD 4.84M 124.71M Dec/2024
Next Science USD 1.67M 7.56M Dec/2024
Polynovo AUD 45.91M 330K Jun/2024
Ramsay Health Care AUD 341.1M 321.2M Dec/2024
ResMed USD 1.21B 687.51M Jun/2025
Sigma Healthcare AUD 16.65M 3.68M Jan/2023
Sonic Healthcare AUD 645M 25.39M Jun/2024
Telix Pharmaceuticals AUD 710.35M 587.11M Dec/2024